Impact of concomitant treatment of non-chronic total occlusion lesions at the time of chronic total occlusion intervention.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 01 2020
Historique:
received: 17 01 2019
revised: 27 05 2019
accepted: 27 06 2019
pubmed: 16 7 2019
medline: 24 11 2020
entrez: 15 7 2019
Statut: ppublish

Résumé

During chronic total occlusion (CTO) percutaneous coronary intervention (PCI), sometimes non-CTO lesions are also treated. We compared the clinical and procedural characteristics and outcomes of CTO PCIs with and without concomitant treatment of a non-CTO lesion in a contemporary multicenter CTO registry. Of the 3598 CTO PCIs performed at 21 centers between 2012 and 2018, 814 (23%) also included PCI of at least one non-CTO lesion. Patients in whom non-CTO lesions were treated were older (65 ± 10 vs. 64 ± 10 years, p = 0.03), more likely to present with an acute coronary syndrome (32% vs. 23%, p < 0.01), and less likely to undergo PCI of a right coronary artery (RCA) CTO (46% vs. 58%, p < 0.01). The most common non-CTO lesion location was the left anterior descending artery (31%), followed by the circumflex (29%) and the RCA (25%).Combined non-CTO and CTO-PCI procedures had similar technical (88% vs. 87%, p = 0.33) and procedural (85% vs. 85%, p = 0.74) success and major in-hospital complication rates (3.4% vs. 2.7%, p = 0.23), but had longer procedure duration (131 [88, 201] vs. 117 [75, 179] minutes, p < 0.01), higher patient air kerma radiation dose (3.0 [1.9, 4.8] vs. 2.8 [1.5, 4.6] Gray, p < 0.01) and larger contrast volume (300 [220, 380] vs. 250 [180, 350] ml, p < 0.01). Combined CTO PCI with PCI of non-CTO lesions is associated with similar success and major in-hospital complication rates compared with cases in which only CTOs were treated, but requires longer procedure duration and higher radiation dose and contrast volume.

Sections du résumé

BACKGROUND
During chronic total occlusion (CTO) percutaneous coronary intervention (PCI), sometimes non-CTO lesions are also treated.
METHODS
We compared the clinical and procedural characteristics and outcomes of CTO PCIs with and without concomitant treatment of a non-CTO lesion in a contemporary multicenter CTO registry.
RESULTS
Of the 3598 CTO PCIs performed at 21 centers between 2012 and 2018, 814 (23%) also included PCI of at least one non-CTO lesion. Patients in whom non-CTO lesions were treated were older (65 ± 10 vs. 64 ± 10 years, p = 0.03), more likely to present with an acute coronary syndrome (32% vs. 23%, p < 0.01), and less likely to undergo PCI of a right coronary artery (RCA) CTO (46% vs. 58%, p < 0.01). The most common non-CTO lesion location was the left anterior descending artery (31%), followed by the circumflex (29%) and the RCA (25%).Combined non-CTO and CTO-PCI procedures had similar technical (88% vs. 87%, p = 0.33) and procedural (85% vs. 85%, p = 0.74) success and major in-hospital complication rates (3.4% vs. 2.7%, p = 0.23), but had longer procedure duration (131 [88, 201] vs. 117 [75, 179] minutes, p < 0.01), higher patient air kerma radiation dose (3.0 [1.9, 4.8] vs. 2.8 [1.5, 4.6] Gray, p < 0.01) and larger contrast volume (300 [220, 380] vs. 250 [180, 350] ml, p < 0.01).
CONCLUSIONS
Combined CTO PCI with PCI of non-CTO lesions is associated with similar success and major in-hospital complication rates compared with cases in which only CTOs were treated, but requires longer procedure duration and higher radiation dose and contrast volume.

Identifiants

pubmed: 31301862
pii: S0167-5273(18)37361-3
doi: 10.1016/j.ijcard.2019.06.077
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

75-80

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Iosif Xenogiannis (I)

Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Dimitri Karmpaliotis (D)

Columbia University, New York, NY, USA.

Khaldoon Alaswad (K)

Henry Ford Hospital, Detroit, MI, USA.

Farouc A Jaffer (FA)

Massachusetts General Hospital, Boston, MA, USA.

Robert W Yeh (RW)

Beth Israel Deaconess Medical Center, Boston, MA, USA.

Mitul Patel (M)

VA San Diego Healthcare System and University of California San Diego, La Jolla, CA, USA.

Ehtisham Mahmud (E)

VA San Diego Healthcare System and University of California San Diego, La Jolla, CA, USA.

James W Choi (JW)

Baylor Heart and Vascular Hospital, Dallas, TX, USA.

M Nicholas Burke (MN)

Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Anthony H Doing (AH)

Medical Center of the Rockies, Loveland, CO, USA.

Phil Dattilo (P)

Medical Center of the Rockies, Loveland, CO, USA.

Catalin Toma (C)

University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Barry Uretsky (B)

VA Central Arkansas Healthcare System, Little Rock, AR, USA.

Oleg Krestyaninov (O)

Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia.

Dmitrii Khelimskii (D)

Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia.

Elizabeth Holper (E)

The Heart Hospital Baylor Plano, Plano, TX, USA.

Srinivasa Potluri (S)

The Heart Hospital Baylor Plano, Plano, TX, USA.

R Michael Wyman (RM)

Torrance Memorial Medical Center, Torrance, CA, USA.

David E Kandzari (DE)

Piedmont Heart Institute, Atlanta, GA, USA.

Santiago Garcia (S)

Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Michalis Koutouzis (M)

Red Cross Hospital of Athens, Athens, Greece.

Ioannis Tsiafoutis (I)

Red Cross Hospital of Athens, Athens, Greece.

Jaikirshan J Khatri (JJ)

Cleveland Clinic, Cleveland, OH, USA.

Wissam Jaber (W)

Emory University Hospital Midtown, Atlanta, GA, USA.

Habib Samady (H)

Emory University Hospital Midtown, Atlanta, GA, USA.

Brian K Jefferson (BK)

Tristar Centennial Medical Center, Nashville, TN, USA.

Taral Patel (T)

Tristar Centennial Medical Center, Nashville, TN, USA.

Jeffrey W Moses (JW)

Columbia University, New York, NY, USA.

Nicholas J Lembo (NJ)

Columbia University, New York, NY, USA.

Manish Parikh (M)

Columbia University, New York, NY, USA.

Ajay J Kirtane (AJ)

Columbia University, New York, NY, USA.

Ziad A Ali (ZA)

Columbia University, New York, NY, USA.

Fotis Gkargkoulas (F)

Columbia University, New York, NY, USA.

Peter Tajti (P)

Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA; University of Szeged, Division of Invasive Cardiology, Second Department of Internal Medicine and Cardiology Center, Szeged, Hungary.

Allison B Hall (AB)

Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Bavana V Rangan (BV)

VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX, USA.

Shuaib Abdullah (S)

VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX, USA.

Subhash Banerjee (S)

VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX, USA.

Emmanouil S Brilakis (ES)

Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA. Electronic address: esbrilakis@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH